#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Brain injury Wolfram syndrome Erythema multiforme Colon cancer Granulomatosis with polyangiitis KBG syndrome Anaemia Germ cell cancer Antiphospholipid antibodies Depression Immune-mediated myositis Shprintzen-Goldberg syndrome Non-Hodgkin's lymphoma refractory Warm autoimmune haemolytic anaemia Colorectal cancer metastatic More trials…

    Learn about Rare Diseases

    Langerhans cell sarcoma – Diagnostics Acute respiratory distress syndrome CADASIL Activated PI3 kinase delta syndrome – Basic Information Cytokine release syndrome – Diagnostics Uterine leiomyosarcoma – Life with Disease Myelodysplastic syndrome – Diagnostics Lymphatic malformation – Trials in Disease Cholangitis sclerosing – Life with Disease Leiomyosarcoma metastatic – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Resmetirom Bempikibart Canis Familiaris (553) Heterodimeric Interleukin-15 Mcla-129 Proline Kd050 Naproxen Sodium Cendakimab Keto-Valine Calcium GSKVX000000034797 Epirubicin Trandolapril 2-DEOXY-D-GLUCOSE Retinol Palmitate SARACATINIB NALDEMEDINE Gemcitabine Hydrochloride 18F-Fludarabine Amisulpride More therapies…

    Learn about Your Condition

    Alveolar rhabdomyosarcoma Aortic stenosis Circulatory collapse Dengue fever Hyperoxaluria Radius fracture Peyronie's disease Coronary artery occlusion Myxofibrosarcoma Basal cell naevus syndrome Diphtheria Hernia repair Arginase deficiency Chronic hepatitis C Aplasia pure red cell More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Somogy Varmegyei Kaposi Mor Oktato Korhaz

Somogy Varmegyei Kaposi Mor Oktato Korhaz

Tallian Gyula Utca 20-32, Kaposvar, 7400, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Fulvestrant
    • Camizestrant
    Belgium France Hungary Italy Poland Portugal +1

  • Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

    Not recruiting

    2 1
    Investigated Drugs:
    • Ab-1002
    Austria Belgium Bulgaria Germany Hungary The Netherlands +3

  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Avelumab
    • ZELENECTIDE PEVEDOTIN
    • Carboplatin
    Austria Belgium Bulgaria Czechia Denmark France +12

  • Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    Investigated Drugs:
    • Bomedemstat
    • Hydroxycarbamide
    Austria Denmark France Germany Hungary Italy +3

  • Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Olaparib
    • Bevacizumab
    • Durvalumab
    Austria Belgium Bulgaria Denmark Finland France +6

  • Study of Lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Drugs:
    • Lutikizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Golcadomide
    • Ibrutinib
    Czechia Denmark France Germany Hungary The Netherlands +1

  • Study on the Safety and Tolerability of Abelacimab Compared to Rivaroxaban in Patients with Atrial Fibrillation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Abelacimab
    • Rivaroxaban
    Czechia Hungary Poland

  • Study of Venetoclax and Azacitidine for Maintenance Therapy in Patients with Acute Myeloid Leukemia in First Remission After Chemotherapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia (in remission)
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    Czechia France Germany Greece Hungary Italy +1

  • Study Comparing Epcoritamab with Chemotherapy for Patients with Relapsed or Refractory B-cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Codeine Phosphate
    • Dexamethasone Isonicotinate
    Austria Belgium Denmark Finland France Germany +7
Previous Page
1 … 4 5 6 7 8 … 12
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!